Evidence map›Paper›PMID 37374019›Full record

ArticleLife (Basel, Switzerland)2023

Validation of the NAT Chagas IVD Kit for the Detection and Quantification of

Otacilio C Moreira, Alice Gomes Fernandes, Natalia Lins da Silva Gomes, Carolina Messias Dos Santos, Thiago Jacomasso, Alexandre Dias Tavares Costa, Lucas de O Rossetti Nascimento, Alejandro Marcel Hasslocher-Moreno, Pedro Emmanuel Alvarenga Americano do Brasil, Luis Gustavo Morello and 3 more

Abstract read
In one paragraph

Article in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Parasite Burden ofMicroorganisms · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Otacilio C MoreiraReal Time PCR Platform RPT09A, Laboratory of Molecular Virology and Parasitology, Oswaldo Cruz Institute/Fiocruz, Rio de Janeiro 21040-900, Brazil.ORCID 0000-0002-5340-8697
Alice Gomes FernandesLaboratory of Molecular Biology and Endemic Diseases, Oswaldo Cruz Institute/Fiocruz, Rio de Janeiro 21040-900, Brazil.
Natalia Lins da Silva GomesReal Time PCR Platform RPT09A, Laboratory of Molecular Virology and Parasitology, Oswaldo Cruz Institute/Fiocruz, Rio de Janeiro 21040-900, Brazil.
Carolina Messias Dos SantosLaboratory of Molecular Biology and Endemic Diseases, Oswaldo Cruz Institute/Fiocruz, Rio de Janeiro 21040-900, Brazil.
Thiago JacomassoInstituto de Biologia Molecular do Paraná, Curitiba 81350-010, Brazil.ORCID 0000-0002-1348-1523
Alexandre Dias Tavares CostaLaboratory for Applied Science and Technology in Health, Carlos Chagas Institute/Fiocruz, Curitiba 81310-020, Brazil.ORCID 0000-0001-8434-2152
Lucas de O Rossetti NascimentoInstituto de Biologia Molecular do Paraná, Curitiba 81350-010, Brazil.
Alejandro Marcel Hasslocher-MorenoLaboratory of Clinical Research in Chagas Disease, Evandro Chagas National Institute of Infectious Diseases/Fiocruz, Rio de Janeiro 21040-360, Brazil.
Pedro Emmanuel Alvarenga Americano do BrasilLaboratory of Clinical Research in Chagas Disease, Evandro Chagas National Institute of Infectious Diseases/Fiocruz, Rio de Janeiro 21040-360, Brazil.
Luis Gustavo MorelloInstituto de Biologia Molecular do Paraná, Curitiba 81350-010, Brazil.
Fabricio Klerynton MarchiniInstituto de Biologia Molecular do Paraná, Curitiba 81350-010, Brazil.
Marco Aurelio KriegerLaboratory for Applied Science and Technology in Health, Carlos Chagas Institute/Fiocruz, Curitiba 81310-020, Brazil.
Constança BrittoLaboratory of Molecular Biology and Endemic Diseases, Oswaldo Cruz Institute/Fiocruz, Rio de Janeiro 21040-900, Brazil.ORCID 0000-0003-0788-7030

Funding

Coordenação de Aperfeicoamento de Pessoal de Nível Superior Finance Code 001Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro O.C.M. and C.B are CNE research fellows of FAPERJNational Council for Scientific and Technological Development O.C.M. is a research fellow of CNPq 1D and C.B. is is a research fellow of CNPq 1BPrograma de Desenvolvimento Tecnológico em Insumos para Saúde RID-34
6 · The paper itself

Abstract

In the absence of validated biomarkers to control the cure of Chagas disease, PCR-based diagnosis is being used as the main tool for an early indication of therapeutic failure. However, since it is considered a technique of complex reproducibility, mainly due to difficulties in establishing accurate controls to guarantee the quality of the reaction, the use of PCR for Chagas disease diagnosis is restricted to specialized centers. In an effort to disseminate the molecular diagnosis of Chagas disease and its applications, new diagnostic kits based on qPCR have been made available in the market in recent years. Here, we show the results of the validation of the NAT Chagas kit (Nucleic Acid Test for Chagas Disease) for the detection and quantification of

Indexed as

Chagas diseasemolecular diagnosticsNAT Chagasparasite loadreal-time PCR

Identifiers

PMID37374019
PMCPMC10300704

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.